An Open-Label Single-Arm Clinical Trial to Evaluate the Efficacy of Propranolol Ointment in Infantile Hemangioma

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs041190041

Enrollment

Registered

2019-06-13

Start date

2019-07-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infantile hemangioma Hemangioma

Interventions

The patient's guardian applies appropriate amounts of propranolol topical application twice a day to the entire affected area for infantile hemangioma

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with 35- to 150-day-old infantile hemangiomas at enrollment

Exclusion criteria

Exclusion criteria: 1. Patients with life-threatening infantile hemangioma 2. Patients with hypoglycemia, hypo tension, bradycardia, heart failure

Design outcomes

Primary

Measure	Time frame
Effective rate for infantile hemangioma at 24 weeks	—

Secondary

Measure	Time frame
1. Effective rate for infantile hemangioma at 12 weeks 2. Area, length and color change of infantile hemangioma after 12 weeks and 24 weeks	—

Contacts

Public ContactEiko Nagata

Hamamatsu University Hospital

amn_e@hama-med.ac.jp+81-53-435-2006

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026